These included record offices, Ex-Servicemen Contributory Health Scheme (ECHS), Army Welfare Placement Organisation (AWPO), ...

Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future ...

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- . (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today ...

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering ... biopharmaceutical company developing ...

Abpro Corporation, a biotechnology company with the mission of improving the lives of those facing severe and ...

GEA will develop and commission proprietary bioreactors for Believer’s cell-cultivation technology ... The HD144 employs drop ...

Apply now for 1791 apprentice positions with North Western Railway! Open to candidates with a 10th-grade qualification and ...

“During the third quarter and at the recent SITC conference, we presented data from our Phase 1a trial of ELI-002 in mKRAS-driven solid tumors, showing tumor biomarker reductions, robust T cell ...

This drug release inhibits cell proliferation, thereby reducing the likelihood ... in-stent restenosis (when a previous stent has failed), and cases where stent placement may be technically ...

November 12, 2024908 Devices Inc. misses on earnings expectations. Reported EPS is $-0.84495 EPS, expectations were $-0.28.

Good day, and welcome to the Bionano third quarter 2024 earnings conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to David Holmes from ...